Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01890278 : Phase II Trial of Conventional Versus IMRT Whole Brain Radiotherapy for Brain Metastases
AgesMin: 18 Years Max: N/A

Inclusion Criteria:

- Evidence of at least one brain metastasis on a gadolinium contrast-enhanced MRI

- Pathologic/histological/cytologic proof of a diagnosis of a non-hematopoietic
malignancy within 5 years of study entry.

- Patient ?18 years of age?

- Fall into RTOG Recursive Partition Analysis (RPA) class I or II.

- Karnofsky Performance Score ?70. (See Appendix III)

- Biopsy done at least 1 week prior to registration. (This requirement does not apply
to stereotactic biopsies.)

Exclusion Criteria:

- Contraindication to MR imaging such as implanted metal devices or foreign bodies,
severe claustrophobia.

- Creatinine level > 1.4 mg/dl drawn ?30 days prior to study entry.

- Severe, active co-morbitities.

- Unstable angina, and/or congestive heart failure requiring hospitalization within the
last 6 months.

- Transmural myocardial infarction within the last 6 months

- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of

- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

- Uncontrolled, clinically significant cardiac arrhythmias

- Pregnancy
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557